Catalent Expert Invited to Present on Maximizing Early Drug Development at the Prague-Weizmann Summer School
Since 2004, Catalent has been involved in more than half of all new molecular entities approved by the FDA. Dr. Harris will use his personal, as well as the company’s experience to address the factors that need to be considered during early drug development in his presentation on Tuesday, Sept. 3 at 9:40 a.m., entitled “Improving the Chance of Success in Early Drug Development”. During his presentation, he will discuss how a holistic approach to development can mitigate against risks and increase the chance of a compound surviving the clinical trial process to reach patients.
Dr. Harris has over 35 years’ experience in the pharmaceutical industry. He started his career in technical support roles with R.P. Scherer, Warner Lambert and Glaxo Wellcome, before spending time in academia as a Research Fellow at the University of Manchester. For the past 15 years, Dr. Harris has worked in the pharmaceutical contract development and manufacturing sector, holding senior technical roles with Quay Pharma, Capsugel, Penn Pharma and Juniper Pharma Services (now part of Catalent). He has overseen the development of numerous new drug candidates for clinical evaluation and maintains a keen interest in technologies for enhancing oral bioavailability for ‘challenging’ compounds, and the development of pediatric medicines.
To arrange a meeting with any of the attending Catalent experts at the event, contact Richard Kerns at NEPR – richard@nepr.agency
Notes for Editors
About Catalent
Catalent is the leading global provider of advanced delivery technologies and development and manufacturing solutions for drugs, biologics, gene therapies and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs over 11,000 people, including over 1,800 scientists, at more than 30 facilities across five continents, and in fiscal year 2018 generated approximately $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com
More products. Better treatments. Reliably supplied.™